Autor: Żołnierek, Jakub - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: O SOLIDARNOŚCI WOBEC LOSU I PRZEZNACZENIA. NOWE PROPOZYCJE AVISHAIA MARGALITA (ON BETRAYAL, 2017)
Autorzy:: ŻOŁNIEREK, Jakub
Powiązania:: https://bibliotekanauki.pl/articles/909855.pdf
Data publikacji:: 2017-06-15
Wydawca:: Uniwersytet im. Adama Mickiewicza w Poznaniu
Źródło:: Historia@Teoria; 2017, 2, 4; 223-230
2450-8047
Pojawia się w:: Historia@Teoria
Dostawca treści:: Biblioteka Nauki

Artykuł

Skocz do pozycji: 2.

Tytuł:: Abiraterone acetate - 10 clinically relevant facts
Autorzy:: Żołnierek, Jakub
Powiązania:: https://bibliotekanauki.pl/articles/2047213.pdf
Data publikacji:: 2021-09-30
Wydawca:: Medical Education
Tematy:: prostate cancer
systemic therapy
hormone therapy
abiraterone acetate
Opis:: Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary – the higher efficacy of treatment with its influence on improving patients’ overall survival and the specific mechanism of action of drugs used in systemic therapy lead to growing population of men suffering from prostate cancer in general and, specifically – patients with castration resistance. It is hormone therapy to play the key role in systemic treatment of prostate cancer with increasing significance of novel drugs focused on inhibition of molecular signal transduction mediated by androgen receptor. Abiraterone acetate is the representative of this therapeutic class. The paper describes the most clinically relevant data regarding the drug.
Źródło:: OncoReview; 2021, 11, 3; 80-84
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Skocz do pozycji: 3.

Tytuł:: The first line therapy for intermediate/ high risk patients with advanced renal cell carcinoma according to therapeutic program B.10
Autorzy:: Żołnierek, Jakub
Powiązania:: https://bibliotekanauki.pl/articles/22792533.pdf
Data publikacji:: 2023-08-19
Wydawca:: Medical Education
Tematy:: renal cell carcinoma
intermediate risk group
unfavourable risk group
tyrosine kinases inhibitor
immune check-point inhibitor
Opis:: The purpose of this article is to discuss the use of therapeutic options for the first-line systemic treatment of patients with advanced renal cell carcinoma under the B.10 drug program effective in Poland as of May 2022 - with a focus on intermediate and high-risk patient populations according to the IMDC. The specific situation created by reimbursement conditions with the exclusion of regimens combined with a tyrosine kinase inhibitor and immune checkpoint inhibitors along with the marginalisation of the use of an mTOr inhibitor necessitates a choice between two-drug immunotherapy or an antian giogenic drug in monotherapy. In this context, choosing the right treatment in the context of specific clinical situations is a challenge.
Źródło:: OncoReview; 2023, 13, 2; 48-57
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Informacja